Moreover, we also found that high expression of CaSR was associated with a worse prognosis following chemotherapy in breast cancer patients who did not receive endocrine therapy (Fig. S2A) and in ovarian cancer patients who underwent suboptimal debulking surgery (Fig. S2B). Here, CASR is linked to breast carcinoma.